88 related articles for article (PubMed ID: 12929273)
1. A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis.
Choudhury KB; Mallik C; Sharma S; Choudhury DB; Maiti S; Roy C
Indian J Palliat Care; 2011 Sep; 17(3):210-8. PubMed ID: 22346045
[TBL] [Abstract][Full Text] [Related]
2. Acute unilateral anterior uveitis following zoledronic acid infusion: A case report.
Anandasayanan K; Malaravan M; Suganthan N
SAGE Open Med Case Rep; 2020; 8():2050313X20944305. PubMed ID: 32742658
[TBL] [Abstract][Full Text] [Related]
3. Importance of antiresorptive therapies for patients with bone metastases from solid tumors.
Talreja DB
Cancer Manag Res; 2012; 4():287-97. PubMed ID: 23049278
[TBL] [Abstract][Full Text] [Related]
4. Current approaches to bone-targeted therapy in genitourinary malignancies.
Mulders PF
Ther Adv Urol; 2012 Oct; 4(5):219-32. PubMed ID: 23024704
[TBL] [Abstract][Full Text] [Related]
5. Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Miceli TS; Colson K; Faiman BM; Miller K; Tariman JD;
Clin J Oncol Nurs; 2011 Aug; 15 Suppl(0):9-23. PubMed ID: 21816707
[TBL] [Abstract][Full Text] [Related]
6. Improving management of patients with advanced cancer.
Drudge-Coates L
Patient Prefer Adherence; 2010 Dec; 4():415-24. PubMed ID: 21206517
[TBL] [Abstract][Full Text] [Related]
7. Management of bone metastases in breast cancer.
Lipton A
Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
[TBL] [Abstract][Full Text] [Related]
8. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for zoledronic acid treatment of patients with bone metastases.
Berenson JR
Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
[TBL] [Abstract][Full Text] [Related]
11. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
